JLS Fund
JLS is a venture capital fund focused primarily on neuroscience, mental health and enabling tools and infrastructure.
| Platform |  | Pricing | Only free issues | Publishes | Daily |
|---|---|---|---|---|---|
| Issues | 159 | Founded | a year ago | Last Issue | 9 days ago |
| Active | |||||
Read this Newsletter
jlsfund.substack.comLatest Issues
Paradromics Partners With Siemens to Improve Brain Implant Surgery
Siemens Healthineers is teaming up with neurotechnology company Paradromics to develop a new brain-imaging platform designed to improve the accuracy of brain-computer interface (BCI) implants.
These particular implants are being developed...
New Non-Opioid Pain Drug Delivers Promising Phase 3 Results
TLC BioSciences just reported positive Phase 3 results for an experimental pain medication that could offer patients longer-lasting relief after surgery while reducing their need for opioids.
The drug, TLC590, is a non-opioid, extended-rel...
Arrowhead Pharmaceuticals' Experimental Alzheimer's Drug Delivers Promising Early Results
Arrowhead Pharmaceuticals has reported encouraging early clinical results for ARO-MAPT, an experimental treatment designed to reduce a protein closely associated with Alzheimer’s disease.
In an ongoing Phase 1/2a clinical trial, the drug r...
Eton Pharmaceuticals and Aquestive Therapeutics Team Up to Bring New Epilepsy Treatment to Patients
Eton Pharmaceuticals and Aquestive Therapeutics have announced a new partnership to bring an experimental seizure-rescue treatment called Libervant to patients in the United States.
Unlike traditional rescue medications that are administer...
IGC Pharma Unveils New AI Platform to Help Identify Alzheimer's Risk Earlier
IGC Pharma (NYSE American: IGC) has introduced a new artificial intelligence platform designed to help identify people at risk of developing Alzheimer’s disease and give doctors a way to monitor their brain health over time.
Called PRISM,...
Audience Metrics
Subscribers, engagement, traffic and sponsorship for JLS Fund.
| Subscribers | Engagement | 70 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
JLS is a venture capital fund focused primarily on neuroscience, mental health and enabling tools and infrastructure.
Frequently Asked Questions
How can I access the email archive for JLS Fund?
You can find recent issues that have been published by JLS Fund on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does JLS Fund have?
To see how many people subscribe to JLS Fund, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in JLS Fund?
Newsletter advertising can be extremely effective when it's done right. Before you pitch JLS Fund as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like JLS Fund?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact JLS Fund using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to JLS Fund?
Scroll up to where it says Related Newsletters to see other publications like JLS Fund. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact JLS Fund?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.